Point-of-care faecal calprotectin testing in patients with paediatric inflammatory bowel disease during the COVID-19 pandemic

Jere, Mwansa; Garrick, Vikki; Curtis, Lee; Tayler, Rachel; Gervais, Lisa; Gerasimidis, Konstantinos; Hansen, Richard

doi:10.1136/bmjgast-2021-000631

Cited by 3 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fecal calprotectin levels could be a non-invasive tool for monitoring disease activity and treatment response in children with COVID-19 patients with gastrointestinal involvement. Serial fecal calprotectin measurements may help clinicians assess the resolution of intestinal inflammation over time and guide therapeutic interventions[ 116 ].…”

Section: Discussionmentioning

confidence: 99%

Fecal calprotectin in pediatric gastrointestinal diseases: Pros and cons

Al-Beltagi,

Saeed,

Bediwy

et al. 2024

World J Clin Pediatr

View full text Add to dashboard Cite

BACKGROUND Fecal calprotectin is a valuable biomarker for assessing intestinal inflammation in pediatric gastrointestinal diseases. However, its role, pros, and cons in various conditions must be comprehensively elucidated. AIM To explore the role of fecal calprotectin in pediatric gastrointestinal diseases, including its advantages and limitations. METHODS A comprehensive search was conducted on PubMed, PubMed Central, Google Scholar, and other scientific research engines until February 24, 2024. The review included 88 research articles, 56 review articles, six meta-analyses, two systematic reviews, two consensus papers, and two letters to the editors. RESULTS Fecal calprotectin is a non-invasive marker for detecting intestinal inflammation and monitoring disease activity in pediatric conditions such as functional gastrointestinal disorders, inflammatory bowel disease, coeliac disease, coronavirus disease 2019-induced gastrointestinal disorders, gastroenteritis, and cystic fibrosis-associated intestinal pathology. However, its lack of specificity and susceptibility to various confounding factors pose challenges in interpretation. Despite these limitations, fecal calprotectin offers significant advantages in diagnosing, monitoring, and managing pediatric gastrointestinal diseases. CONCLUSION Fecal calprotectin holds promise as a valuable tool in pediatric gastroenterology, offering insights into disease activity, treatment response, and prognosis. Standardized protocols and guidelines are needed to optimize its clinical utility and mitigate interpretation challenges. Further research is warranted to address the identified limitations and enhance our understanding of fecal calprotectin in pediatric gastrointestinal diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Fecal calprotectin in pediatric gastrointestinal diseases: Pros and cons

Al-Beltagi,

Saeed,

Bediwy

et al. 2024

World J Clin Pediatr

View full text Add to dashboard Cite

show abstract

Gastrointestinal Bleeding in the Neonate: Updates on Diagnostics, Therapeutics, and Management

Reeves,

James-Davis,

Khan

2023

NeoReviews

View full text Add to dashboard Cite

Gastrointestinal bleeding (GIB) is a relatively uncommon presentation in the NICU. GIB in neonates includes a broad spectrum of disease morbidity, from minor reflux symptoms and growth failure to severe, clinically significant anemia requiring critical care resuscitation. Over the last several years, multiple diagnostic tools including fecal calprotectin and bedside ultrasonography have emerged and demonstrated utility in the early recognition of sources for GIB in neonates. Further evidence has continued to show that traditional medical therapy with intravenous proton pump inhibitors is well-tolerated, and that upper endoscopy has limited diagnostic and therapeutic value. Finally, additional research and quality improvement investigations are warranted to determine how best to prevent, recognize, and manage GIB in critical neonates.

show abstract

iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis

D’Amico

Magro

Caron

et al. 2023

JCM

View full text Add to dashboard Cite

The i Support Therapy–Access to Rapid Treatment (iSTART) was an initiative to improve patient-centered management in mild-to-moderate ulcerative colitis (UC). Our aim was to update the iSTART recommendations in order to include fecal calprotectin (FC) in the monitoring of patients with UC and improve their management. Twelve physicians from nine countries worldwide attended a virtual international consensus meeting on 4 May 2022. Data from three systematic reviews were analyzed, and a new systematic review investigating all studies reporting measurement of FC at home was conducted. Based on literature evidence, statements were formulated, discussed, and approved by voting. Statements were considered approved if at least 75% of participants agreed with a proposed statement. Fourteen statements were approved. Based on this consensus, FC measurement should be routinely performed for monitoring patients with mild-to-moderate UC to identify disease relapses early and initiate an appropriate treatment. Further studies are needed to assess whether self-monitoring of FC is associated with better disease control and improved patients’ quality of life.

show abstract

Point-of-care faecal calprotectin testing in patients with paediatric inflammatory bowel disease during the COVID-19 pandemic

Cited by 3 publications

References 19 publications

Fecal calprotectin in pediatric gastrointestinal diseases: Pros and cons

Fecal calprotectin in pediatric gastrointestinal diseases: Pros and cons

Gastrointestinal Bleeding in the Neonate: Updates on Diagnostics, Therapeutics, and Management

iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis

Contact Info

Product

Resources

About